Publication | Open Access
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
38
Citations
12
References
2022
Year
Hematological MalignancyIsatuximab-treated PatientsPrimary OutcomesMedicineImmunologyHematologyImmune Checkpoint InhibitorImmunotherapyOncologyRelapsed/refractory Multiple Myeloma
Not available.
| Year | Citations | |
|---|---|---|
Page 1
Page 1